MRNA logo

Moderna, Inc. (MRNA) Cash From Financing

Annual CFF:

$56.00M+$1.43B(+104.07%)
December 31, 2024

Summary

  • As of today, MRNA annual cash from financing is $56.00 million, with the most recent change of +$1.43 billion (+104.07%) on December 31, 2024.
  • During the last 3 years, MRNA annual cash from financing has risen by +$929.00 million (+106.41%).
  • MRNA annual cash from financing is now -97.25% below its all-time high of $2.03 billion, reached on December 31, 2020.

Performance

MRNA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherMRNAcash flow metrics

Quarterly CFF:

-$1.00M-$10.00M(-111.11%)
September 30, 2025

Summary

  • As of today, MRNA quarterly cash from financing is -$1.00 million, with the most recent change of -$10.00 million (-111.11%) on September 30, 2025.
  • Over the past year, MRNA quarterly cash from financing has dropped by -$12.00 million (-109.09%).
  • MRNA quarterly cash from financing is now -100.07% below its all-time high of $1.38 billion, reached on June 30, 2020.

Performance

MRNA Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherMRNAcash flow metrics

TTM CFF:

$9.00M-$12.00M(-57.14%)
September 30, 2025

Summary

  • As of today, MRNA TTM cash from financing is $9.00 million, with the most recent change of -$12.00 million (-57.14%) on September 30, 2025.
  • Over the past year, MRNA TTM cash from financing has increased by +$59.00 million (+118.00%).
  • MRNA TTM cash from financing is now -99.56% below its all-time high of $2.03 billion, reached on December 31, 2020.

Performance

MRNA TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherMRNAcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

MRNA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+104.1%-109.1%+118.0%
3Y3 Years+106.4%+99.9%+100.2%
5Y5 Years+7.7%-103.4%-99.5%

MRNA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+101.6%-102.9%+99.9%-83.9%+100.2%
5Y5-Year-97.3%+101.6%-102.3%+99.9%-99.6%+100.2%
All-TimeAll-Time-97.3%+101.6%-100.1%+99.9%-99.6%+100.2%

MRNA Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
-$1.00M(-111.1%)
$9.00M(-57.1%)
Jun 2025
-
$9.00M(+125.0%)
$21.00M(-54.3%)
Mar 2025
-
$4.00M(+233.3%)
$46.00M(-17.9%)
Dec 2024
$56.00M(+104.1%)
-$3.00M(-127.3%)
$56.00M(+212.0%)
Sep 2024
-
$11.00M(-67.6%)
-$50.00M(+58.0%)
Jun 2024
-
$34.00M(+142.9%)
-$119.00M(+85.5%)
Mar 2024
-
$14.00M(+112.8%)
-$821.00M(+40.4%)
Dec 2023
-$1.38B(+60.1%)
-$109.00M(-87.9%)
-$1.38B(+19.3%)
Sep 2023
-
-$58.00M(+91.3%)
-$1.71B(+36.6%)
Jun 2023
-
-$668.00M(-23.2%)
-$2.69B(+19.7%)
Mar 2023
-
-$542.00M(-23.7%)
-$3.35B(+2.9%)
Dec 2022
-$3.45B(-295.0%)
-$438.00M(+57.9%)
-$3.45B(+11.2%)
Sep 2022
-
-$1.04B(+21.6%)
-$3.88B(-36.5%)
Jun 2022
-
-$1.33B(-106.7%)
-$2.84B(-84.6%)
Mar 2022
-
-$642.00M(+26.5%)
-$1.54B(-76.5%)
Dec 2021
-$873.00M(-142.9%)
-$873.00M(>-9900.0%)
-$873.00M(-2079.2%)
Sep 2021
-
-$2.00M(+91.7%)
$44.11M(-41.8%)
Jun 2021
-
-$24.00M(-192.3%)
$75.83M(-94.9%)
Mar 2021
-
$26.00M(-41.1%)
$1.48B(-27.2%)
Dec 2020
$2.03B(+3809.6%)
$44.11M(+48.4%)
$2.03B(+0.7%)
Sep 2020
-
$29.73M(-97.8%)
$2.02B(+0.7%)
Jun 2020
-
$1.38B(+139.0%)
$2.01B(+219.3%)
Mar 2020
-
$578.05M(+1835.4%)
$627.91M(+1152.1%)
Dec 2019
$52.00M(-95.8%)
$29.87M(+88.9%)
$50.15M(-91.6%)
Sep 2019
-
$15.81M(+278.5%)
$596.20M(+4.1%)
Jun 2019
-
$4.18M(+1325.6%)
$572.70M(-15.4%)
Mar 2019
-
$293.00K(-99.9%)
$677.14M(-44.8%)
Dec 2018
$1.23B(>+9900.0%)
$575.91M(+7596.0%)
$1.23B(+88.0%)
Sep 2018
-
-$7.68M(-107.1%)
$652.47M(-1.2%)
Jun 2018
-
$108.61M(-80.3%)
$660.16M(+19.5%)
Mar 2018
-
$550.00M(>+9900.0%)
$552.26M(>+9900.0%)
Dec 2017
$168.00K(-100.0%)
$1.54M(>+9900.0%)
$2.74M(+81.3%)
Sep 2017
-
$10.50K(-98.5%)
$1.51M(-2.5%)
Jun 2017
-
$716.00K(+50.7%)
$1.55M(+85.7%)
Mar 2017
-
$475.10K(+53.3%)
$835.00K(+132.0%)
Dec 2016
$472.91M(>+9900.0%)
-
-
Dec 2016
-
$309.90K(+519.8%)
$359.90K(+619.8%)
Sep 2016
-
$50.00K(>+9900.0%)
$50.00K(-95.4%)
Jun 2016
-
$0.00(0.0%)
$1.09M(0.0%)
Mar 2016
-
$0.00(0.0%)
$1.09M(-0.1%)
Dec 2015
$1.10M(-80.8%)
$0.00(-100.0%)
$1.10M(-2.1%)
Sep 2015
-
$1.09M(>+9900.0%)
$1.12M(+5228.6%)
Jun 2015
-
$0.00(-100.0%)
$21.00K(+10.5%)
Mar 2015
-
$1000.00(-95.7%)
$19.00K(-99.7%)
Dec 2014
$5.69M(>+9900.0%)
$23.00K(+866.7%)
$5.69M(+0.3%)
Sep 2014
-
-$3000.00(-50.0%)
$5.68M(+0.0%)
Jun 2014
-
-$2000.00(-100.0%)
$5.68M(+0.0%)
Mar 2014
-
$5.68M(>+9900.0%)
$5.68M(>+9900.0%)
Dec 2013
-$2000.00(-100.1%)
$8000.00(+300.0%)
-$2000.00(-102.3%)
Sep 2013
-
-$4000.00(0.0%)
$86.00K(-4.4%)
Jun 2013
-
-$4000.00(-100.0%)
$90.00K(+295.7%)
Mar 2013
-
-$2000.00(-102.1%)
-$46.00K(-101.8%)
Dec 2012
$2.57M(-84.0%)
$96.00K(>+9900.0%)
$2.57M(-38.6%)
Sep 2012
-
$0.00(+100.0%)
$4.18M(-20.9%)
Jun 2012
-
-$140.00K(-105.4%)
$5.29M(-62.0%)
Mar 2012
-
$2.61M(+52.7%)
$13.93M(-13.1%)
Dec 2011
$16.02M(+28.4%)
$1.71M(+55.0%)
$16.02M(-6.5%)
Sep 2011
-
$1.10M(-87.0%)
$17.14M(+6.4%)
Jun 2011
-
$8.50M(+80.6%)
$16.11M(+51.8%)
Mar 2011
-
$4.71M(+66.3%)
$10.61M(-15.0%)
Dec 2010
$12.48M(+157.1%)
$2.83M(+4189.4%)
$12.48M(+18.4%)
Sep 2010
-
$66.00K(-97.8%)
$10.54M(+0.4%)
Jun 2010
-
$3.01M(-54.3%)
$10.50M(-30.7%)
Mar 2010
-
$6.58M(+640.5%)
$15.15M(+212.2%)
Dec 2009
$4.85M
$888.00K(+2962.1%)
$4.85M(+94.5%)
DateAnnualQuarterlyTTM
Sep 2009
-
$29.00K(-99.6%)
$2.50M(+188.9%)
Jun 2009
-
$7.66M(+305.7%)
$864.00K(+221.5%)
Mar 2009
-
-$3.72M(-153.3%)
-$711.00K(-140.6%)
Dec 2008
$1.75M(-95.7%)
-$1.47M(+8.3%)
$1.75M(-11.7%)
Sep 2008
-
-$1.60M(-126.3%)
$1.99M(-51.3%)
Jun 2008
-
$6.09M(+583.0%)
$4.08M(+378.8%)
Mar 2008
-
-$1.26M(-1.9%)
-$1.46M(-103.6%)
Dec 2007
$41.01M(+157.1%)
-$1.24M(-351.4%)
$41.01M(-12.2%)
Sep 2007
-
$492.00K(-9.1%)
$46.74M(-3.5%)
Jun 2007
-
$541.00K(-98.7%)
$48.41M(-2.5%)
Mar 2007
-
$41.22M(+818.3%)
$49.65M(+211.3%)
Dec 2006
$15.95M(-46.5%)
$4.49M(+107.1%)
$15.95M(+22.9%)
Sep 2006
-
$2.17M(+21.5%)
$12.98M(-65.3%)
Jun 2006
-
$1.78M(-76.2%)
$37.37M(-0.3%)
Mar 2006
-
$7.51M(+395.7%)
$37.48M(+25.8%)
Dec 2005
$29.79M(-56.2%)
$1.51M(-94.3%)
$29.79M(-62.7%)
Sep 2005
-
$26.57M(+1303.3%)
$79.84M(+48.9%)
Jun 2005
-
$1.89M(+1123.2%)
$53.60M(-17.6%)
Mar 2005
-
-$185.00K(-100.4%)
$65.07M(-4.3%)
Dec 2004
$68.00M(+467.8%)
$51.56M(>+9900.0%)
$68.00M(+300.5%)
Sep 2004
-
$328.00K(-97.5%)
$16.98M(-36.3%)
Jun 2004
-
$13.36M(+387.1%)
$26.68M(+76.5%)
Mar 2004
-
$2.74M(+401.5%)
$15.11M(+26.2%)
Dec 2003
$11.97M(+57.9%)
$547.00K(-94.5%)
$11.97M(+1.3%)
Sep 2003
-
$10.02M(+457.8%)
$11.82M(+466.6%)
Jun 2003
-
$1.80M(+558.4%)
$2.09M(+134.6%)
Mar 2003
-
-$392.00K(-200.3%)
$889.00K(-88.3%)
Dec 2002
$7.58M(-41.7%)
$391.00K(+34.8%)
$7.58M(-47.8%)
Sep 2002
-
$290.00K(-51.7%)
$14.54M(-3.7%)
Jun 2002
-
$600.00K(-90.5%)
$15.09M(-1.2%)
Mar 2002
-
$6.30M(-14.1%)
$15.27M(+17.3%)
Dec 2001
$13.02M(>+9900.0%)
$7.34M(+771.1%)
$13.02M(+129.3%)
Sep 2001
-
$843.00K(+8.4%)
$5.68M(+15.5%)
Jun 2001
-
$778.00K(-80.8%)
$4.92M(+20.0%)
Mar 2001
-
$4.05M(>+9900.0%)
$4.10M(+9209.1%)
Dec 2000
$44.00K(+108.8%)
$4000.00(-95.1%)
$44.00K(+173.3%)
Sep 2000
-
$82.00K(+295.2%)
-$60.00K(+88.9%)
Jun 2000
-
-$42.00K(>-9900.0%)
-$542.00K(-8.4%)
Mar 2000
-
$0.00(+100.0%)
-$500.00K(0.0%)
Dec 1999
-$500.00K(-135.7%)
-$100.00K(+75.0%)
-$500.00K(-25.0%)
Sep 1999
-
-$400.00K(>-9900.0%)
-$400.00K(>-9900.0%)
Jun 1999
-
$0.00(0.0%)
$0.00(-100.0%)
Mar 1999
-
$0.00(0.0%)
$1.30M(-7.1%)
Dec 1998
$1.40M(-92.0%)
$0.00(0.0%)
$1.40M(0.0%)
Sep 1998
-
$0.00(-100.0%)
$1.40M(0.0%)
Jun 1998
-
$1.30M(+1200.0%)
$1.40M(+1300.0%)
Mar 1998
-
$100.00K(>+9900.0%)
$100.00K(-99.4%)
Dec 1997
$17.60M(+309.3%)
$0.00(0.0%)
$17.60M(0.0%)
Sep 1997
-
$0.00(0.0%)
$17.60M(+0.6%)
Jun 1997
-
$0.00(-100.0%)
$17.50M(-15.5%)
Mar 1997
-
$17.60M(>+9900.0%)
$20.70M(+567.7%)
Dec 1996
$4.30M(+43.3%)
-
-
Sep 1996
-
-$100.00K(-103.1%)
$3.10M(+3.3%)
Jun 1996
$3.00M(0.0%)
$3.20M(>+9900.0%)
$3.00M(+3.4%)
Mar 1996
-
$0.00(0.0%)
$2.90M(0.0%)
Dec 1995
-
$0.00(+100.0%)
$2.90M(0.0%)
Sep 1995
-
-$200.00K(-106.5%)
$2.90M(-3.3%)
Jun 1995
$3.00M(-37.5%)
$3.10M(>+9900.0%)
$3.00M(+3100.0%)
Mar 1995
-
$0.00(0.0%)
-$100.00K(0.0%)
Dec 1994
-
$0.00(+100.0%)
-$100.00K(-102.2%)
Sep 1994
-
-$100.00K(>-9900.0%)
$4.50M(-6.3%)
Jun 1994
$4.80M
$0.00(0.0%)
$4.80M(0.0%)
Mar 1994
-
$0.00(-100.0%)
$4.80M(0.0%)
Dec 1993
-
$4.60M(+2200.0%)
$4.80M(+2300.0%)
Sep 1993
-
$200.00K
$200.00K

FAQ

  • What is Moderna, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Moderna, Inc.?
  • What is Moderna, Inc. annual cash from financing year-on-year change?
  • What is Moderna, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Moderna, Inc.?
  • What is Moderna, Inc. quarterly cash from financing year-on-year change?
  • What is Moderna, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Moderna, Inc.?
  • What is Moderna, Inc. TTM cash from financing year-on-year change?

What is Moderna, Inc. annual cash from financing?

The current annual cash from financing of MRNA is $56.00M

What is the all-time high annual cash from financing for Moderna, Inc.?

Moderna, Inc. all-time high annual cash from financing is $2.03B

What is Moderna, Inc. annual cash from financing year-on-year change?

Over the past year, MRNA annual cash from financing has changed by +$1.43B (+104.07%)

What is Moderna, Inc. quarterly cash from financing?

The current quarterly cash from financing of MRNA is -$1.00M

What is the all-time high quarterly cash from financing for Moderna, Inc.?

Moderna, Inc. all-time high quarterly cash from financing is $1.38B

What is Moderna, Inc. quarterly cash from financing year-on-year change?

Over the past year, MRNA quarterly cash from financing has changed by -$12.00M (-109.09%)

What is Moderna, Inc. TTM cash from financing?

The current TTM cash from financing of MRNA is $9.00M

What is the all-time high TTM cash from financing for Moderna, Inc.?

Moderna, Inc. all-time high TTM cash from financing is $2.03B

What is Moderna, Inc. TTM cash from financing year-on-year change?

Over the past year, MRNA TTM cash from financing has changed by +$59.00M (+118.00%)
On this page